Organon & Co.
OGN- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821825
In the last 90 days, Organon & Co. insiders filed 0 open-market purchases and 1 sale; 636 institutions reported holding it in 13F filings for Q2 2026, worth $2.92B in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Organon & Co. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Of which not filed for Q2 2023 | Q2 2023 | Change |
|---|---|---|---|---|
| Holders | 769 | 4 | 728 | −37 |
| Shares | 198.3M | 22.0K | 199.0M | +696.1K (+0.4%) |
| Value | $4.67B | $518.1K | $4.13B | −$540.3M (−11.6%) |
4 institutions that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (61)
Institutions that held Organon & Co. at the end of Q2 2023 but not at the end of Q1 2023.
Sold out (98)
Institutions that held Organon & Co. at the end of Q1 2023 and filed for Q2 2023 without it.
Not filed for Q2 2023 yet (4)
Institutions that held Organon & Co. at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Kula Investments, LLC | 20,993 | $493.8K |
| Householder Group Estate & Retirement Specialist, LLC | 803 | $19.0K |
| Baldrige Asset Management LLC | 192 | $5.00K |
| Ahrens Investment Partners LLC | 13 | $306 |